Project Details
Description
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] ≥ 50%), previously untreated, unresectable, locally advanced or metastatic NSCLC. Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
| Status | Active |
|---|---|
| Effective start/end date | 14/10/22 → 14/01/28 |
Collaborative partners
- GlaxoSmithKline (lead)
- Abu Dhabi Health Services Company
Keywords
- Non-small cell lung cancer
- Dostarlimab
- Pembrolizumab
- PD-L1
- GSK4428859A
- EOS884448
- PD-1 Inhibitor
- Immunotherapy
- Belrestotug
- GSK6097608
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents, Immunological
- Antineoplastic Agents
- Immune Checkpoint Inhibitors
- Molecular Mechanisms of Pharmacological Action
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.